Study Roles of Heavy Metals and Essential Metal Dyshomeostasis in Pulmonary Arterial Hypertension Patients

Launched by JIAPENG HUANG · Feb 13, 2021

Keywords

ClinConnect Summary

This clinical trial is investigating the role of heavy metals and essential metals in patients with Pulmonary Arterial Hypertension (PAH). Researchers will study 50 patients from the UofL PAH Clinic, looking at different levels of disease severity, and will also include 10 healthy participants matched by age and gender. The goal is to understand how levels of 31 different metals—both harmful (like lead and arsenic) and necessary (like iron and zinc)—might be related to the condition and its progression over a year.

To participate, you need to be diagnosed with pulmonary hypertension and agree to the study's guidelines. Healthy volunteers who match the age and gender of the PAH patients are also welcome. Participants will have their blood and urine samples collected during routine visits to the clinic every six months, which will help researchers analyze how the concentration of these metals may relate to the severity and treatment of PAH. This study aims to provide insights that could improve understanding and management of the disease, so your contribution could be very valuable!

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • All patients with the diagnosis of pulmonary hypertension
• • Agree to the study protocol
• • Healthy volunteers
• • Age, gender matched controls
• Exclusion Criteria:
• • Younger than 18 years
• • Refusal to participate